Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
Noam Barda, Noa Dagan, Cyrille J. Cohen, et al.
The Lancet (2021) Vol. 398, Iss. 10316, pp. 2093-2100
Open Access | Times Cited: 866

Showing 1-25 of 866 citing articles:

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Delphine Planas, Nell Saunders, Piet Maes, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 671-675
Open Access | Times Cited: 1460
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
Daniel R. Feikin, Melissa M. Higdon, Laith J. Abu‐Raddad, et al.
The Lancet (2022) Vol. 399, Iss. 10328, pp. 924-944
Open Access | Times Cited: 1108
Homologous and Heterologous Covid-19 Booster Vaccinations
Robert L. Atmar, Kirsten E. Lyke, Meagan E. Deming, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 11, pp. 1046-1057
Open Access | Times Cited: 544
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
Shirley Collie, Jared Champion, Harry Moultrie, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 5, pp. 494-496
Open Access | Times Cited: 440
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Alasdair Munro, Leila Janani, Victoria Cornelius, et al.
The Lancet (2021) Vol. 398, Iss. 10318, pp. 2258-2276
Open Access | Times Cited: 430
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 7, pp. 255-263
Open Access | Times Cited: 426
Advances in COVID-19 mRNA vaccine development
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 414
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Mark G. Thompson, Karthik Natarajan, Stephanie A. Irving, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 4, pp. 139-145
Open Access | Times Cited: 397
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 831-837
Open Access | Times Cited: 374
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 19, pp. 1804-1816
Open Access | Times Cited: 367
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Marc Lipsitch, Florian Krammer, Gili Regev‐Yochay, et al.
Nature reviews. Immunology (2021) Vol. 22, Iss. 1, pp. 57-65
Open Access | Times Cited: 311
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
Edson Duarte Moreira, Nicholas Kitchin, Xia Xu, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 20, pp. 1910-1921
Open Access | Times Cited: 311
Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review
Santenna Chenchula, Padmavathi Karunakaran, Sushil Sharma, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 2969-2976
Open Access | Times Cited: 301
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study
Cristina Menni, Anna May, Lorenzo Polidori, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 7, pp. 1002-1010
Open Access | Times Cited: 290
Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
Rekha Khandia, Shailja Singhal, Taha Alqahtani, et al.
Environmental Research (2022) Vol. 209, pp. 112816-112816
Open Access | Times Cited: 282
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Ori Magen, Jacob Waxman, Maya Makov-Assif, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 17, pp. 1603-1614
Open Access | Times Cited: 269
SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis
Paddy Ssentongo, Anna E. Ssentongo, Navya Voleti, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 226
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
Matthew Gagné, Juan I. Moliva, Kathryn E. Foulds, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1556-1571.e18
Open Access | Times Cited: 213
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
John P. Evans, Cong Zeng, Claire Carlin, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 637
Open Access | Times Cited: 203
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study
Alejandro Jara, Eduardo A. Undurraga, José R. Zubizarreta, et al.
The Lancet Global Health (2022) Vol. 10, Iss. 6, pp. e798-e806
Open Access | Times Cited: 192
COVID-19 vaccination: The road ahead
Daniel M. Altmann, Rosemary J. Boyton
Science (2022) Vol. 375, Iss. 6585, pp. 1127-1132
Closed Access | Times Cited: 184
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales
Utkarsh Agrawal, Stuart Bedston, Colin McCowan, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1305-1320
Open Access | Times Cited: 179
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, et al.
BMJ (2022), pp. e072141-e072141
Open Access | Times Cited: 163
Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis
Wing Ying Au, Peter Pak‐Hang Cheung
BMJ (2022), pp. e069989-e069989
Open Access | Times Cited: 129
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study
Mie Agermose Gram, Hanne‐Dorthe Emborg, Astrid Blicher Schelde, et al.
PLoS Medicine (2022) Vol. 19, Iss. 9, pp. e1003992-e1003992
Open Access | Times Cited: 128
Page 1 - Next Page

Scroll to top